Search results
14 lis 2023 · Salmonella Vaccine Study in Oxford is a first-in-human study of a novel vaccine against invasive non-typhoidal Salmonellosis (iNTS), a neglected disease largely affecting low- and middle-income countries.
14 lis 2023 · Here, a first-in-human study of a novel vaccine (iNTS-GMMA) containing S. Typhimurium and S. Enteritidis Generalised Modules for Membrane Antigens (GMMA) outer membrane vesicles is presented. METHOD AND ANALYSIS: The Salmonella Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA ...
22 paź 2024 · The study provided insights for public health, emphasising the importance of strengthening resistance monitoring, optimising vaccination strategies, formulating localised interventions, rationally allocating public health resources, improving environmental hygiene, promoting interdisciplinary collaboration, and raising public awareness and ...
14 lis 2023 · Method and analysis: The Salmonella Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA vaccine. Healthy adult volunteers will be randomised to receive three intramuscular injections of the iNTS-GMMA vaccine, containing equal quantities of S .
14 cze 2017 · This review compiles the current knowledge acquired from past and present studies that have helped to define key parameters instrumental in the design of an efficient anti-Salmonella vaccine. Mechanisms of Salmonella -host interaction resulting in bacterial uptake, as well as the innate and adaptive anti- Salmonella protective immunity, are ...
2 cze 2023 · While a trivalent typhoid/nontyphoidal Salmonella vaccine is attractive for Africa, and a bivalent enteric fever vaccine for Asia, a quadrivalent vaccine covering the 4 main disease-causing serovars of Salmonella enterica would provide a single vaccine option for global Salmonella coverage.
In this review we focus on (1) recent advances in live attenuated Salmonella vaccine development, (2) improvements in expression of foreign antigens in carrier vaccines and (3) adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine ...
